Why Zoetis (ZTS) Shares Are Trading Lower Today - Zoetis (NYSE:ZTS)

Zoetis Inc ZTS has reported Q2 FY22 revenue of $2.05 billion, an increase of 5% Y/Y, almost in line with the consensus of $2.04
Adjusted EPS was $1.20, +1% Y/Y, missing the consensus of $1.22.
Revenue in the U.S. segment was $1.09 billion, +9%.
Sales of companion animal products increased 13%, driven by growth across the parasiticide portfolio, primarily Simparica Trio for dogs.
Sales of livestock products declined due to generic competition for Draxxin and continued weakness in beef & dairy consumer markets.
The poultry portfolio declined due to the expanded use of lower-cost alternatives and generic competition for Zoamix, the Company's option for antibiotics in medicated feed additives.
Sales of swine products grew primarily from higher disease prevalence and favorable market conditions for producers.
Revenue in the International segment increased 2% to $943 million.
Guidance: Zoetis expects FY22 sales of $8.23 - $8.33 billion, compared to $8.23 - $8.38 billion expected earlier and the consensus of $8.29 billion.
The company forecasts adjusted EPS of $4.97 - $5.05, down from the previous guidance of $4.99 - $5.09.
Price Action: ZTS shares are down 3.84% at $173.25 during the market session on the last check Thursday.

Zoetis's Clocks Mixed Q2 Earnings, Lowers FY22 Profit Outlook